What the warnings say
Section 5.2 of the US label covers acute pancreatitis in all its forms, including haemorrhagic and necrotising pancreatitis in which part of the pancreas bleeds or dies, notes that some cases have been fatal, and applies to GLP-1 medicines as a class including Wegovy®. Prescribers are asked to watch for persistent or severe abdominal pain, at times radiating to the back, with or without nausea or vomiting, and to stop Wegovy® if pancreatitis is suspected. [1]
The EU product information adds that semaglutide should not be restarted if pancreatitis is confirmed and that caution is needed in people with a history of pancreatitis. [2] The Canadian monograph says the same about restarting and notes Wegovy® was not studied in people with chronic pancreatitis or acute pancreatitis within the previous six months. [3]
Confirmed cases and enzyme changes
In the adult weight-reduction trials, possible cases went through formal review, which the label calls adjudication. The table sets those cases next to the large heart trial and the enzyme findings. [1][2][3]
| Finding and source | Placebo | Wegovy® / semaglutide |
|---|---|---|
| Confirmed acute pancreatitis, adult weight trials, US and Canada [1][3] | 1 person (under 0.1 per 100 patient-years) | 4 people (0.2 per 100 patient-years) |
| Confirmed acute pancreatitis, SELECT heart trial, EU and Canada [2][3] | 24 people (0.3%) | 17 people (0.2%) |
| Average rise in amylase from baseline, weight trials [1] | not observed | 15% to 16% |
| Average rise in lipase from baseline, weight trials [1] | not observed | 39% |
| Lipase above 3 times the upper normal limit, MASH trial [1] | 1.3% (5 of 374) | 4.7% (35 of 750) |
Reading those numbers
The weight-trial counts are small: four on Wegovy® out of more than 2,000 treated adults, plus one further confirmed case in another trial. Expressed per 100 patient-years, that is about one case for every 500 years of treatment. [1] SELECT, with more than 8,800 people on each arm followed for about three years, gives a larger base, and there the semaglutide arm had slightly fewer confirmed cases than placebo. [2][3]
Amylase and lipase are pancreatic enzymes measured in blood tests. Both rose on average in adults and teenagers on Wegovy®, a change not seen with placebo, and in a trial in people with MASH, a liver condition, lipase rose above three times the normal limit more often on Wegovy®. The label says the clinical significance of these rises is unknown without other signs or symptoms. [1] A raised enzyme on its own is not a diagnosis.
Reports after approval, and what studies show
Section 6.2 lists acute and necrotising pancreatitis, sometimes resulting in death, among reactions reported voluntarily since semaglutide came to market; frequency cannot be estimated from such reports and a causal link cannot always be shown. [1]
Randomised-trial evidence points the other way on frequency. A 2017 meta-analysis of 113 trials in type 2 diabetes found no significant difference in pancreatitis between GLP-1 medicines and comparators, [6] a 2020 update of 43 longer trials reached the same conclusion, [7] and a 2025 meta-analysis of 55 placebo-controlled trials found GLP-1 medicines probably have little or no effect on pancreatitis risk. [5] A US insurance-claims study of people without diabetes using semaglutide or liraglutide for weight loss reported a higher adjusted risk of pancreatitis than with bupropion-naltrexone, but with a very wide confidence interval and only two cases among 613 semaglutide users. [8] Observational data of this kind cannot prove cause, and trials may miss rare events, which is why the warning stays.
Why it may happen, and other causes
- In the label: pancreatitis is a class warning for GLP-1 medicines; the label describes it but does not explain how it arises. [1]
- A possible indirect route, not proven: NIH names gallstones as the most common cause of acute pancreatitis, [9] and gallstones are more frequent on Wegovy® (1.6% versus 0.7% in adults). [1] No document says this link accounts for pancreatitis cases on Wegovy®.
- Other common causes: heavy alcohol use, genetic disorders of the pancreas, some medicines, very high blood triglycerides, high blood calcium, abdominal injury, infections and certain procedures on the bile and pancreatic ducts. [9][10]
- Medicines MedlinePlus names in this context include oestrogens, corticosteroids, sulfonamides, thiazide diuretics and azathioprine. [10]
Signs that mean stop and call
For stomach-area pain that is severe and persistent, whether or not you also feel sick or vomit, the Medication Guide says to stop Wegovy® and contact your healthcare provider at once; the pain can travel from the abdomen through to the back. It also asks you to tell your provider before starting if you have or have had pancreas problems. [1] NIH adds that people with acute pancreatitis usually look and feel seriously ill, and lists fever or chills, a fast heartbeat, shortness of breath and yellowing of the skin or eyes as signs of severe disease needing care right away. [9]
Section 12.3 gives semaglutide a half-life of about one week, with the medicine remaining in the circulation for roughly five to seven weeks after the last 2.4 mg or 7.2 mg dose, [1] one reason clinicians ask exactly when the last injection was given. Novo Nordisk’s patient page repeats the stop-and-call instruction. [4]
Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- Severe stomach-area pain that will not go away, sometimes reaching the back, with or without nausea or vomiting
Contact: Stop Wegovy® and call your provider right away; emergency care if severe
Medication Guide [1]
- Belly pain with fever or chills, a fast heartbeat, shortness of breath or yellow skin or eyes
Contact: Emergency care
NIDDK [9]
Today
- Upper belly pain with fever, yellowing or clay-coloured stools
Contact: Your prescriber the same day
Medication Guide [1]